AstraZeneca Collaborates with MGH to Accelerate Digital Health Solutions
AstraZeneca’s AZD7442 Meet its Primary Endpoints in P-III TACKLE Trial for the Treatment of COVID-19
Shots:
- The companies collaborated to accelerate digital health solutions with the goal of improving the patient’s outcomes and care with chronic illness
- MGH will utilize AstraZeneca’s AMAZE disease management platform for heart failure and asthma management studies. The companies plan to expand the use of AMAZE across multiple chronic diseases, following the success of heart failure and asthma studies
- Through remote monitoring, AMAZE identifies at-risk patients and delivers insights to the clinical care team at POC to improve the management of complex patient populations. The digital platform includes a patient app and clinician dashboard intends to speed up evidence-based clinical practice
Click here to read full press release/ article | Ref: BusinessWire | Image: Al Jazeera